Matthew R Beymer1,2, Jennifer L Gildner3, Ian W Holloway3, Raphael J Landovitz2,4. 1. 1 Department of Health and Mental Health Services, Los Angeles LGBT Center , Los Angeles, California. 2. 2 Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California , Los Angeles, Los Angeles, California. 3. 3 Department of Social Welfare, Luskin School of Public Affairs, University of California , Los Angeles, Los Angeles, California. 4. 4 Center for Clinical AIDS Research and Education (CARE), University of California , Los Angeles, Los Angeles, California.
Abstract
PURPOSE: Pre-exposure prophylaxis (PrEP) is an effective strategy to prevent HIV. However, low uptake of daily oral PrEP since Food and Drug Administration approval and low medication adherence among users have stimulated the investigation of other modalities for delivery, such as injectable PrEP and on-demand PrEP. The objective of this study was to determine the demographic and behavioral predictors of willingness to try alternative PrEP delivery mechanisms among young men who have sex with men (YMSM) who stated that they were unwilling to try daily oral PrEP. METHODS: YMSM in California were recruited through geosocial networking applications; we analyzed a subsample who stated that they were either ambivalent about trying or unwilling to try daily oral PrEP (n = 265). We used chi-square and Fisher's exact tests to determine characteristics associated with willingness to try injectable PrEP, willingness to try on-demand PrEP, and willingness to try either alternative form. RESULTS: For individuals who stated that they would not be willing to try daily oral PrEP, ∼85% were willing to try on-demand and/or injectable PrEP. Individuals who reported some college or more reported greater willingness to try injectable PrEP (adjusted odds ratio [aOR]: 2.92; 95% confidence interval [CI]: 1.32-6.46), on-demand PrEP (aOR: 2.28; 95% CI: 1.06-4.90), or either method (aOR: 5.54; 95% CI: 1.78-17.22). CONCLUSION: Future research should determine how to enhance uptake of emerging forms of PrEP among the individuals most at risk for HIV.
PURPOSE: Pre-exposure prophylaxis (PrEP) is an effective strategy to prevent HIV. However, low uptake of daily oral PrEP since Food and Drug Administration approval and low medication adherence among users have stimulated the investigation of other modalities for delivery, such as injectable PrEP and on-demand PrEP. The objective of this study was to determine the demographic and behavioral predictors of willingness to try alternative PrEP delivery mechanisms among young men who have sex with men (YMSM) who stated that they were unwilling to try daily oral PrEP. METHODS: YMSM in California were recruited through geosocial networking applications; we analyzed a subsample who stated that they were either ambivalent about trying or unwilling to try daily oral PrEP (n = 265). We used chi-square and Fisher's exact tests to determine characteristics associated with willingness to try injectable PrEP, willingness to try on-demand PrEP, and willingness to try either alternative form. RESULTS: For individuals who stated that they would not be willing to try daily oral PrEP, ∼85% were willing to try on-demand and/or injectable PrEP. Individuals who reported some college or more reported greater willingness to try injectable PrEP (adjusted odds ratio [aOR]: 2.92; 95% confidence interval [CI]: 1.32-6.46), on-demand PrEP (aOR: 2.28; 95% CI: 1.06-4.90), or either method (aOR: 5.54; 95% CI: 1.78-17.22). CONCLUSION: Future research should determine how to enhance uptake of emerging forms of PrEP among the individuals most at risk for HIV.
Entities:
Keywords:
HIV pre-exposure prophylaxis; HIV prevention; gay/bisexual men; men who have sex with men
Authors: H Jonathon Rendina; Thomas H F Whitfield; Christian Grov; Tyrel J Starks; Jeffrey T Parsons Journal: Soc Sci Med Date: 2016-11-18 Impact factor: 4.634
Authors: Jeffrey T Parsons; H Jonathon Rendina; Jonathan M Lassiter; Thomas H F Whitfield; Tyrel J Starks; Christian Grov Journal: J Acquir Immune Defic Syndr Date: 2017-03-01 Impact factor: 3.731
Authors: Peter L Anderson; David V Glidden; Albert Liu; Susan Buchbinder; Javier R Lama; Juan Vicente Guanira; Vanessa McMahan; Lane R Bushman; Martín Casapía; Orlando Montoya-Herrera; Valdilea G Veloso; Kenneth H Mayer; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Esper Georges Kallás; Robert M Grant Journal: Sci Transl Med Date: 2012-09-12 Impact factor: 17.956
Authors: Jeffrey T Parsons; H Jonathon Rendina; Christian Grov; Ana Ventuneac; Brian Mustanski Journal: J Acquir Immune Defic Syndr Date: 2015-04-01 Impact factor: 3.731
Authors: Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Ian W Holloway; Ryan Dougherty; Jennifer Gildner; Sean C Beougher; Craig Pulsipher; Jorge A Montoya; Aaron Plant; Arleen Leibowitz Journal: J Acquir Immune Defic Syndr Date: 2017-01-01 Impact factor: 3.771
Authors: Eric William Hall; Walid Heneine; Travis Sanchez; Robert Craig Sineath; Patrick Sullivan Journal: J Med Internet Res Date: 2016-05-19 Impact factor: 5.428
Authors: Jacqueline Ellison; Jacob J van den Berg; Madeline C Montgomery; Jun Tao; Rashmi Pashankar; Matthew J Mimiaga; Philip A Chan Journal: AIDS Patient Care STDS Date: 2019-10-11 Impact factor: 5.078
Authors: Ian W Holloway; Diane Tan; Robert A Bednarczyk; Vincent L Fenimore; Laura Randall; Chelsea S Lutz; Paula M Frew Journal: Arch Sex Behav Date: 2019-10-18
Authors: Matthew E Levy; Anya Agopian; Manya Magnus; Anthony Rawls; Jenevieve Opoku; Michael Kharfen; Alan E Greenberg; Irene Kuo Journal: J Acquir Immune Defic Syndr Date: 2021-03-01 Impact factor: 3.771
Authors: Gordon Mansergh; Krishna Kiran Kota; Rob Stephenson; Sabina Hirshfield; Patrick Sullivan Journal: J Int AIDS Soc Date: 2021-01 Impact factor: 6.707
Authors: Nwora Lance Okeke; Tony McLaurin; Ruth Gilliam-Phillips; David H Wagner; Valerie J Barnwell; Yolanda M Johnson; Osaffo James; Padonda B Webb; Sharon D Parker; Bendu Hill; Mehri S McKellar; John T Mitchell Journal: BMC Public Health Date: 2021-05-19 Impact factor: 3.295